Alpha memo: metformin exercise protocol mismatch

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

Minor issues

• Receipt 1 (2010) is presented with a meeting abstract DOI; the full publication of this work appears in a different venue, but the abstract excerpt substantiates the described design and population, so this is a minor provenance note rather than a grounding defect.

Reviewer note

The memo delivers exactly what an alpha-memo should: one bounded research signal (metformin–exercise interaction may not transfer cleanly from an enhancing signal on fasting insulin secretion in prediabetes to an HbA1c endpoint in type 2 diabetes), supported by a tight two-receipt bundle. The title, topic anchors (metformin, exercise training), and the cited sources align: Receipt 1 is the prediabetes RCT (n=32) on fasting insulin secretion, and Receipt 2 is the DARE trial (n=251, T2D) examining whether metformin modifies aerobic/resistance/combined exercise effects on HbA1c. The contrast is explicitly framed as a cross-population, cross-endpoint comparison rather than a single-anchor claim. Hedging is appropriate throughout ("made plausible," "may attenuate," "tentative and confounded"), and limitations are specific and material (sample size, endpoint family, population differences). The falsifier is concrete and falsifiable. No clinical, policy, or consensus claims are made. Source excerpts corroborate the receipt descriptions. No injected instructions detected.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis